{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T22:01:29Z","timestamp":1784584889170,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.thromres.2022.06.015","type":"journal-article","created":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T11:13:53Z","timestamp":1657365233000},"page":"22-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Factor IX antibodies and tolerance in hemophilia B in the Nordic countries \u2013 The impact of F9 variants and complications"],"prefix":"10.1016","volume":"217","author":[{"given":"Kristina","family":"Kihlberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fariba","family":"Baghaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Bruzelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Funding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e5l Andre","family":"Holme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riitta","family":"Lassila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vuokko","family":"Nummi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Ranta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Strandberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine Gretenkort","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Berntorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Astermark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2022.06.015_bb0005","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","article-title":"The past and future of haemophilia: diagnosis, treatments, and its complications","volume":"388","author":"Peyvandi","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2022.06.015_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.06.015_bb0015","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/j.1365-2516.2009.02039.x","article-title":"Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997\u20132006)","volume":"15","author":"Chitlur","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.06.015_bb0020","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1160\/TH12-05-0302","article-title":"Assessment of the F9 genotype-specific FIX inhibitor risks and characterisation of 10 novel severe F9 defects in the first molecular series of Argentinian patients with haemophilia B","volume":"109","author":"Radic","year":"2013","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.06.015_bb0025","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.blre.2017.08.007","article-title":"Haemophilia B: where are we now and what does the future hold?","volume":"32","author":"Dolan","year":"2018","journal-title":"Blood Rev."},{"key":"10.1016\/j.thromres.2022.06.015_bb0030","first-page":"635","article-title":"Molecular genotyping of the Italian cohort of patients with hemophilia B","volume":"90","author":"Belvini","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2022.06.015_bb0035","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3324\/haematol.2019.239160","article-title":"Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study","volume":"106","author":"Male","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2022.06.015_bb0040","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1055\/s-0037-1617018","article-title":"ITI with high-dose FIX and combined immunosuppressive therapy in a patient with severe haemophilia B and inhibitor","volume":"29","author":"Beutel","year":"2009","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.thromres.2022.06.015_bb0045","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2516.2007.01584.x","article-title":"Immune tolerance induction with mycophenolate-mofetil in two children with haemophilia B and inhibitor","volume":"14","author":"Klarmann","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.06.015_bb0050","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1046\/j.1365-2516.1999.00195.x","article-title":"Tolerance induction using the Malm\u00f6 treatment model 1982\u20131995","volume":"5","author":"Freiburghaus","year":"1999","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.06.015_bb0055","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/ejh.13193","article-title":"Inhibitors in haemophilia a and B: management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients","volume":"102","author":"Ljung","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.thromres.2022.06.015_bb0060","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0037-1612943","article-title":"The North American Immune Tolerance Registry: practices, outcomes, outcome predictors","volume":"87","author":"DiMichele","year":"2002","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.06.015_bb0065","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3389\/fimmu.2020.00563","article-title":"Prevalence and incidence of non-neutralizing antibodies in congenital hemophilia a\u2014a systematic review and meta-analysis","volume":"11","author":"Abdi","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.thromres.2022.06.015_bb0070","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1182\/blood-2016-06-720086","article-title":"Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A","volume":"129","author":"Cannav\u00f2","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2022.06.015_bb0075","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1182\/blood-2015-10-675512","article-title":"FVIII-binding IgG modulates FVIII half-life in patients with severe and moderate hemophilia a without inhibitors","volume":"128","author":"Hofbauer","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2022.06.015_bb0080","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1182\/bloodadvances.2020002731","article-title":"The prospective hemophilia inhibitor PUP study reveals distinct antibody signatures prior to FVIII inhibitor development","volume":"4","author":"Reipert","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.thromres.2022.06.015_bb0085","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1111\/jth.13438","article-title":"Survey of the anti-factor IX immunoglobulin profiles in patients with hemophilia B using a fluorescence-based immunoassay","volume":"14","author":"Boylan","year":"2016","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.06.015_bb0090","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/hae.14299","article-title":"Treatment outcomes in persons with severe haemophilia B in the Nordic region: the B-NORD study","volume":"27","author":"Kihlberg","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.06.015_bb0095","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/j.1538-7836.2012.04705.x","article-title":"Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance","volume":"10","author":"Miller","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.06.015_bb0100","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1600-0609.1976.tb00330.x","article-title":"Immunosuppressive treatment in haemophiliacs with inhibitors to factor VIII and factor IX","volume":"16","author":"Nilsson","year":"1976","journal-title":"Scand. J. Haematol."},{"key":"10.1016\/j.thromres.2022.06.015_bb0105","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/j.1460-2075.1989.tb03474.x","article-title":"Molecular pathology of haemophilia B","volume":"8","author":"Green","year":"1989","journal-title":"EMBO J."},{"key":"10.1016\/j.thromres.2022.06.015_bb0110","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/hae.12854","article-title":"Mutation analysis of Swedish haemophilia B families - high frequency of unique mutations","volume":"22","author":"M\u00e5rtensson","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.06.015_bb0115","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1093\/bioinformatics\/bty897","article-title":"VarSome: the human genomic variant search engine","volume":"35","author":"Kopanos","year":"2019","journal-title":"Bioinformatics"},{"key":"10.1016\/j.thromres.2022.06.015_bb0120","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/jth.12276","article-title":"An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B","volume":"11","author":"Rallapalli","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.06.015_bb0125","unstructured":"Factor IX Gene Variant Database. http:\/\/www.factorix.org\/, (n.d.). http:\/\/www.factorix.org\/ (accessed March 5, 2021)."},{"key":"10.1016\/j.thromres.2022.06.015_bb0130","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/j.1651-2227.2002.tb02854.x","article-title":"Inhibitors in the Swedish population with severe haemophilia A and B: a 20-year survey","volume":"91","author":"Knobe","year":"2002","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.thromres.2022.06.015_bb0135","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/hae.14357","article-title":"The B-Natural study\u2014the outcome of immune tolerance induction therapy in patients with severe haemophilia B","volume":"27","author":"Astermark","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.06.015_bb0140","first-page":"48","article-title":"Immune tolerance induction and the treatment of hemophilia.Malm\u00f6 protocol update","volume":"85","author":"Berntorp","year":"2000","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2022.06.015_bb0145","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/j.1365-2516.2007.01446.x","article-title":"Induction of immune tolerance using rituximab in a child with severe haemophilia B with inhibitors and anaphylaxis to factor IX","volume":"16","author":"Barnes","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.06.015_bb0150","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-2516.2006.01411.x","article-title":"Cyclosporin a can achieve immune tolerance in a patient with severe haemophilia B and refractory inhibitors","volume":"13","author":"Cross","year":"2007","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.06.015_bb0155","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.5482\/HAMO-14-01-0010","article-title":"Successful second ITI with factor IX and combined immunosuppressive therapy: a patient with severe haemophilia B and recurrence of a factor IX inhibitor","volume":"34","author":"Holstein","year":"2014","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.thromres.2022.06.015_bb0160","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/MBC.0000000000000288","article-title":"Successful treatment of immune tolerance induction with rituximab in a patient with severe hemophilia B and inhibitor","volume":"26","author":"Kobayashi","year":"2015","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.thromres.2022.06.015_bb0165","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/hae.13457","article-title":"Successful multi-modal immune tolerance induction for factor IX deficiency with inhibitors and allergic reactions","volume":"24","author":"Kuhn","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.06.015_bb0170","doi-asserted-by":"crossref","DOI":"10.1186\/s13052-015-0116-8","article-title":"Desensitization and immune tolerance induction in children with severe factor IX deficiency; inhibitors and adverse reactions to replacement therapy: a case-report and literature review","volume":"41","author":"Bon","year":"2015","journal-title":"Ital. J. Pediatr."},{"key":"10.1016\/j.thromres.2022.06.015_bb0175","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1111\/hae.13926","article-title":"Eradication of factor IX neutralizing and anaphylactic inhibitors in a patient with severe haemophilia B using cyclophosphamide immune suppression and factor IX desensitization","volume":"26","author":"Greenmyer","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2022.06.015_bb0180","unstructured":"Nordic Hemophilia Council, Nord. Hemoph. Counc. (n.d.). http:\/\/nordhemophilia.org\/ (accessed January 26, 2022)."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384822003097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384822003097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:48:57Z","timestamp":1758736137000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384822003097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":36,"alternative-id":["S0049384822003097"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2022.06.015","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factor IX antibodies and tolerance in hemophilia B in the Nordic countries \u2013 The impact of F9 variants and complications","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2022.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}